Abstract
Introduction

Toll-like receptors (TLRs) are a family of pattern recognition receptors (PRRs) responsible for recognizing conserved pathogen-associated molecular patterns (PAMPs). Engagement of TLRs initiates intracellular signalling pathways leading to the synthesis and secretion of various cytokines and chemokines by cells of the innate immune system. TLR-induced innate immune responses are also a prerequisite for the generation of most adaptive immune responses. TLRs therefore represent the first line of host defence against pathogens and play a pivotal role in both innate and adaptive immunity. In recent years, increasing evidence demonstrates that, under many pathological conditions, endogenous stimulators can activate TLR signalling to trigger a sterile inflammatory response. We review research progress on endogenous TLR ligands and their biological effects in non-infectious inflammation conditions such as tissue injury, tissue repair and regeneration, autoimmune disease and tumorigenesis.
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. TLR1 forms heterodimers with TLR2 (TLR1/2) and recognizes triacyl lipopeptides [3] .
TLR2 in concert with TLR1 or TLR6 recognizes a wide variety of PAMPs, including peptidoglycan, lipopeptides and lipoproteins of gram
ϩ bacteria, mycoplasma lipopeptides and fungal zymosan [4] .
Heterodimerization of TLRs extends the spectrum of ligands recognized. TLR4, together with its extracellular components such as MD-2 and CD14, recognizes lipopolysaccharide (LPS), a constituent of cell walls of gram -bac-
teria [5] . In addition, studies in mice show that TLR4 recognizes not only bacterial motifs, but also viral motifs [6] and the plant product taxol [7] . TLR6 in association with TLR2 (TLR2/6) recognizes diacyl lipopeptides [8] . TLRs recognizing nucleic acids are localized in cytoplasmic compartments where they detect DNA and RNA derived from viruses and bacteria. TLR3 recognizes double-strand RNA [9] , and TLR7 and TLR8 are responsive to the single-strand RNA [10] found during viral replication. TLR9 recognizes unmethylated deoxycytidyl-phosphate-deoxyguanosine (CpG) motifs commonly present in bacterial and viral genomes [11] . TLR5 recognizes bacterial flagellin [12] and TLR11 in mouse is responsive to a profilin-like molecule from the protozoan parasite Toxoplasma gondii [13] . Human TLR11 has been reported to be non-functional because of the presence of a stop codon in the gene [14] . TLR10 is able to homodimerize or heterodimerize with TLR1 and TLR2, but its ligand remains unknown [15] . Fig. 1) [2] . Each [2] . TIRAP mediates the activation of the MyD88-dependent pathway downstream of TLR2 and TLR4 [16, 17] . [18, 19] . TRAM selectively mediates the TRIF-dependent pathway downstream of TLR4, but not TLR3 [20] .
Engagement of TLRs by PAMPs triggers intracellular signalling cascades through a set of toll/interleukin-1 receptor (TIR)-domain-containing adaptors, including myeloid differentiation primary response protein 88 (MyD88), TIR domain-containing adaptor protein (TIRAP/Mal), TIR domain-containing adaptor inducing interferon (IFN)-␤ (TRIF/TICAM1) and TRIF-related adaptor molecule (TRAM/TICAM2) (
TRIF is recruited to TLR3 and TLR4 and mediates a MyD88-independent (TRIF-dependent) signalling pathway, leading to the activation of the late phase of NF-B and IFN regulatory factor 3 (IRF3) and the subsequent production of type I IFN (IFN-␣/␤), IFN-inducible gene products and an immune regulatory response
Endogenous TLR ligands
Recognition of microbial ligands fails to explain all functions of TLRs [21] . In addition to microbial PAMPs, an increasing number of endogenous stimulators are being reported as candidate ligands of TLRs (for review [22] [23] [24] [25] [22, 26] such as fibronectin [27] , heparan sulphate [28] , biglycan [29] , fibrinogen [30] 
Polysaccharides and proteoglycan
Biglycan [29] , CD138 [23] , heparan sulphate [28] , oligosaccharides of hyaluronan [31] and hyaluronan breakdown fragments [32] [33] [34] 63] Nucleic acids DNA [64, 65] , RNA [66, 67] , mRNA [68, 69] [30] , fibronectin [27] , heparan sulphate [28] , HMGB1 [21, 41] [24, 114, 116] ). [117] . MyD88-deficient mice are EAE resistant and show no brain inflammation. This protection is due partly to TLR9 signalling [117] . These data indicate that both TLR9 and MyD88 are essential modulators of EAE and implicate an endogenous TLR9-dependent signal exerting an encephalitogenic effect [117] . As TLR9 is functionally expressed in microglia, it is likely that the ligand in the CNS is derived from cells that are damaged by the pathogenic effector T cells [118] . However, research results are inconsistent [119, 120] . It has been reported that TLR4-and TLR9-deficient mice exhibit more severe EAE symptoms than wild-type mice [119] and that stimulation of TLR3 with poly I:C induces IFN-␤ secretion and suppresses EAE [120] .
Ischemia and reperfusion injury
Ischemia/reperfusion injury is implicated in a broad array of pathological conditions such as myocardial infarction; cerebral stroke; and hepatic, renal and intestinal ischemia as well as following cardiovascular and transplant surgery [77]. The hallmark of these pathologies is extreme inflammation. Massive tissue injury with a large number of cells undergoing necrosis lead to the release of DAMPs from dead and dying cells resulting in the activation of TLRs and sterile inflammation (Fig. 2) [79]. Most of the evidence for the existence of endogenous TLR ligands is based on the study of I/R injury, the majority of endogenous ligands are likely to be involved in the activation of TLRs in I/R injury [80-82], but a strong necrosis-induced inflammatory response may, at least in part, be mediated by HMGB1 [83]. The injury promoting roles of TLR4 are manifested in almost all organs as demonstrated by the protection of TLR4-deficient mice after hepatic, renal, cardiac and cerebral I/R [83-87]. Deficiency of TLR2, TLR4 or MyD88 leads to an attenuated myocardial inflammation, a smaller infarction size, better preserved ventricular function, and reduced ventricular remodelling after ischemic injury [88]. Much evidence points to endogenous TLR ligands as mediators of I/R-induced inflammation. The endotoxin blockade using the LPS-neutralizing agent (recombinant bactericidal/permeabilityincreasing protein) fails to protect mouse livers from warm I/R injury, and LPS-independent, heat-sensitive protein molecules contained in liver perfusates activate macrophages to produce TNF-␣ through the TLR4 pathway, providing evidence that endogenous TLR4 ligands are critical in the pathogenesis of liver I/R injury [89]. HMGB1 expression is rapidly up-regulated in hepatic and renal I/R injury and blockade of HMGB1 by a neutralizing antibody dramatically reduces hepatic injury in wild-
Augmented TLR expression has been observed within the central nervous system (CNS) during EAE, even in the absence of apparent microbial involvement
Bacterial DNA [122] [123] [124] . The inflammation resolves more quickly in TLR4-deficient experimental arthritic mice than in control mice [125] and blocking TLR4 in mice with collagen-induced arthritis leads to reduced disease severity [126] . Serum and synovial fluid from RA patients stimulate TLR4-expressing CHO cells to up-regulate CD25 [127] and RA synovial membrane culture supernatants are able to activate human macrophages via TLR signalling, suggesting the involvement of an endogenous ligand in the pathogenesis of RA [128] . [130] . RNA released from necrotic synovial fluid cells was recently shown to activate synovial fibroblasts via TLR3 [124] . ChromatinIgG complexes activate B cells by dual engagement of antigen receptors and TLR9 to produce rheumatoid factor, a class of autoantibodies [64] . DNase II-deficient mice develop chronic polyarthritis resembling human RA due to excessive release of DNA following cell death, which may contribute to TLR9 activation [131] . Tenascin-C is an extracellular matrix glycoprotein specifically expressed in inflamed rheumatoid joints [37] . [114] . DNA and DNA-associated autoantigens activate autoreactive B cells via sequential engagement of the BCR and TLR9 [64, 65] , whereas RNA and RNA-associated autoantigens react through BCR/TLR7 [66] . Autoimmune-prone mice, lacking the TLR adaptor protein MyD88, have markedly reduced autoantibody titres, further supporting the suggestion that TLRs play a key role in autoantibody responses in SLE [66] . [133] [134] [135] . Moreover, it has been reported recently that dying tumour cells release endogenous TLR ligands [41, 74] that are involved in solid tumour progression [136, 137] and probably in leukemic cell growth [23] . [139] and can stimulate adjacent multiple myeloma cells [23] . [140] . TLR4 serves as a functional receptor for serum amyloid A 3 in pre-metastatic lungs. Serum amyloid A 3 is induced by S100A8 and S100A9, stimulates NF-B signalling and facilitates metastasis [141] . Small fragments of hyaluronan in melanoma might promote tumour invasiveness by inducing matrix metalloprotease-and cytokine expression in a TLR4-dependent manner [142] . In addition, heparan sulphate proteoglycan CD138 expressed on multiple myeloma cells can bind to TLR4 and act as an autocrine survival factor. Soluble CD138 and heparanase levels correlate with poor prognoses [23] . [143] . In addition, even mechanical ventilation significantly increases endogenous TLR4 ligands in bronchoalveolar lavage fluid and induces a TLR4-dependent inflammatory response in healthy mice [144] .
Several putative endogenous TLR ligands have been associated with RA. HMGB1 is detectable in the synovial fluid of RA patients [129] and its expression is increased in synovial fibroblasts of RA patients compared to osteoarthritis patients, and this may stimulate the release of pro-inflammatory cytokines by fibroblasts
Tenascin-Cdeficient mice show rapid resolution of acute joint inflammation and are protected from erosive arthritis [37]. Administration of exogenous tenascin-C promotes joint inflammation in vivo and induces cytokine synthesis in in vitro cultures in a TLR4-dependent manner, indicating that tenascin-C is an endogenous TLR activator essential for maintaining inflammation in arthritic joint disease [37]. It has been demonstrated that mammalian DNA and RNA, in the form of immune complexes, are potent self-antigens for TLR9 and TLR7, respectively, and induce IFN-␣ production by plasmacytoid pre-dendritic cells, which may promote systemic lupus erythematosus (SLE) [67, 132]. As TLR7 and TLR9 are located in cytoplasmic compartments, it is believed that these autoantigens gain access to them through a receptor-mediated delivery. One such access route is the B cell receptor (BCR)-mediated endocytosis, which is available not only for microorganisms but also for endogenous ligands that are liberated from damaged cells and recognized by an autoreactive BCR
Tumorigenesis and tumour progression
The study of the association of TLR signalling with tumours focuses primarily on the following three aspects. It has been found that TLR signal-mediated chronic inflammation is involved in tumorigenesis and that the activation of TLR signalling induces an antitumour T-cell response [41]. In addition, evidence indicates that TLRs are also expressed in tumour cells and tissues, and TLR signalling contributes to tumour progression and chemoresistance
HMGB1 is a major putative tumour-related TLR ligand. It has been revealed that the ability of chemotherapeutic agents to kill tumours is decreased in TLR4-and MyD88-deficient mice [41]. This is mainly attributed to HMGB1, released by chemotherapyinduced cell death, which activates TLR4 expressed by DCs and induces antitumour T-cell immunity
The extracellular matrix proteoglycan versican in Lewis lung carcinoma has been identified as a macrophage activator that acts through TLR2 and its co-receptors TLR6 and CD14 and strongly enhances Lewis lung carcinoma metastatic growth via TLR2/TLR6-mediated TNF-␣ secretion
Other inflammatory responses mediated by endogenous TLR ligands
Several endogenous ligands are involved in the inflammatory responses of the respiratory tract. HSP72 is released and biologically active in the bronchoalveolar lavage fluid and can regulate airway epithelial cell cytokine expression and activate neutrophils via TLR4 [58, 59]. The endogenous oxidized phospholipid oxidized 1-palmitoyl-2-arachidonoyl-phosphatidylcholine (OxPAPC) has been demonstrated recently to induce acute lung injury and cytokine production by lung macrophages through TLR4-TRIF signalling [71]. TLR3 expression is increased in airway epithelial cells from patients with acute respiratory distress syndrome [143]. TLR3-deficiency or administration of anti-TLR3 antibody to wild-type mice protects these animals from hyperoxia-induced lung injury and inflammation in the absence of a viral pathogen, suggesting an important role of TLR3 signalling and the possible involvement of endogenous TLR3 ligands
Endogenous [148] .
Sterile inflammation in the injured nervous system can also be triggered by endogenous TLR signals (for review [149] [152] .
Conclusions
Toll was first found to be a receptor involved in embryonic development of the fly [153] . TLRs, its mammalian homologues, were first discovered in 1997 [154] and were quickly demonstrated to be responsible for the recognition of microbial components [5] . In addition to binding to microbial PAMPs and involvement in host defence against pathogens, TLRs are involved in many sterile inflammation processes. The ability of TLRs to recognize endogenous mediators appears to be necessary for their ability to regulate sterile inflammation [110] . However, the biochemical evidence for the direct interaction of TLRs with endogenous stimulators is limited [35, 61] . Most evidence is provided from in vitro studies which have potential for contamination of bacterial TLR agonists, particularly those from commercial sources or recombinant products expressed in bacterial systems [25, 63] . For example, recombinant human HSP70 preparation has been reported to be contaminated by LPS [155] . Thus, in vivo studies and biochemical evidence are essential for endogenous ligands to be widely accepted. In vivo studies suggest that matrix components biglycan and hyaluronan are endogenous TLR ligands [32, 63] . Although there is ongoing controversy concerning some putative endogenous ligands [110, 156, 157] 
